Please do your own DD using FA +TA
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I have yet to sell this one.........If I do, it'll be a little off the top, after a run up.........wait for a pull back or put the $ in another great looking chart with super good fundamentals........
Like SWKS has,
Fletch
Wonder if Brilacidin can be administered in a shot form rather than in a IV or pill? Like if a person has an infection, the normal course is to go to your doctors office.....The Doc give you a prescription for a antibiotic pill for like 10 days that you take 4 times a day. But this new one (BRILACIDIN) only needs one dose!......so he gives you a shot....like a vaccine,
Fletch :>)
Hello Leo,
We really really need to uplist to the Nasdaq....science looks great.....we are ALL very patiently waiting.....We are ALL in trust.
So lets get it done.......
Thanks,
Fletch
MHO is......once we get uplisted on to the NASDAQ......all our ills will vanish......poooof! Too many consider us a lil stinky pinky and not to be touched with anyones 10' pole,
Fletch
Poster conclusions section.......really like the bold one below,
Fletch
Conclusions
• p53 induction by Kevetrin is non-genotoxic
• Tumors harboring both mutant and wild type p53 can be treated with Kevetrin
• Kevetrin induced apoptotic cell death in wild type p53 and mutant p53 cells through
p53 apoptotic pathways
• Kevetrin stabilized p53 and induced p53 transcriptional targets in wild type p53
• Inhibition of MDM2 by Kevetrin induces transcriptional independent apoptosis
• Kevetrin induced degradation of mutant p53 mediated by reactivation of
MDM2 E3 ligase
• Kevetrin is a potent anti-tumor agent
• Expression of p21 in lymphocytes is a biomarker for Kevetrin
• Kevetrin is in a Phase 1 clinical trial; 3 cohorts have been completed without DLT
Just what is so scary.....are those eyes still intact,
Fletch
Just letting the science play out......quicker better...... :>)
Some of our down trend is "sell in May and go away".....Some is just we have been selling off......so it continues....MM's not helping with small market sell orders dropping share price like 5-10 cents every morning.....(why would anyone SELL a bunch of small market orders at open??) It's just a bit of MANIPULATION....IMVHO only,
Fletch
Edit....We are under valued.... why? BUY MUCH MORE IMHO.......I have been.
Hey Buddy......Then please post the "reference" chart...........
waiting for it,
Fletch :>0....
Not sure if this has been posted and not a lot of new info,
Fletch
http://www.microcapdaily.com/what-do-you-know-about-cellceutix-corp-otcmktsctix/110826/
What Do You Know About Cellceutix Corp (OTCMKTS:CTIX) 0
BY CARRIE RIVERS ON MAY 4, 2015 MEDIA & TECHNOLOGY, MICRO CAP INSIDER
Cellceutix Corp (OTCMKTS:CTIX) recently dropped below $3 a share and has continued to move lower from there. Since hitting $4.93 in the first few days of January CTIX has been in steep decline.
The stock was looking up a few weeks ago after CTIX announced a $30 million stock purchase agreement and another meeting with the FDA to Discuss Phase 2 Clinical Trial for Ulcerative Proctitis Treatment; Cellceutix’s Abstract on Kevetrin to Be Presented at ASCO
In recent news CTIX announced the selection of Dr. Barry Alan Schechter, Dr. Zorik Spektor and Mark Tobin as qualified independent directors and committee members of the Company’s Board of Directors.
CTIX is one of those legendary stories that we love to report on; from pennies a share back in 2011 to recent highs near $5 CTIX has transformed itself as the top most traded stock on the entire bb’s.
It all comes back to Cellceutix chief scientific officer, Dr. Krishna Menon; the man is a real whiz; he played key roles in developing two blockbuster cancer drugs; Gemzar and Alimta for Eli Lilly & Co.(NYSE:LLY) back in the late 90’s.
For CTIX he developed Kevetrin which is currently in Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute. Kevetrin is successful in regulating the p53 pathway that has long been the holy grail of cancer research and big pharma. Industry leaders spent hundreds of millions of dollars trying to achieve what Dr. Krishna Menon has achieved with Kevetrin.
Cellceutix Corp (OTCMKTS:CTIX) is a clinical stage biopharmaceutical company located in Beverly, Massachusetts developing innovative therapies in oncology, dermatology and antimicrobial applications.
CTIX flagship is Brilacidin, a new class of antibiotics called defensin-mimetics, which are modeled after host defense proteins. These are the “front line” of defense in the human immune system and mange suggest Brilacidin could rival Cubist’s (NASDAQ:CBST) Daptomycin as the antibiotic of primary choice.
CTIX recently announced that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation for Brilacidin as a new treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) ahead of its meeting this month with Cellceutix regarding Cellceutix’s planned Phase 3 trial of Brilacidin for ABSSSI. Brilacidin, the Company’s lead drug in a new class of antibiotics called defensin-mimetics, completed a Phase 2b trial in September showing, amongst other things, a single dose of Brilacidin to be as effective in treatment of ABSSSI as a FDA-approved seven-day dosing regimen of daptomycin.
The QIDP designation was established as part of the Generating Antibiotic Incentives Now (GAIN) Act, passed by the U.S. Congress in July 2012, for the purpose of encouraging pharmaceutical companies to develop new antimicrobial drugs to treat serious and life-threatening infections. Receiving QIDP designation means that Brilacidin is now eligible for additional FDA incentives in the approval and marketing path, including Fast Track designation and Priority Review for development and a five-year extension of market exclusivity.
Among the benefits of QIDP is Fast Track and Priority Review status and a five-period of market exclusivity if approved. Cellceutix acquired Brilacidin last year when they purchased the assets of PolyMedix.
On April 1 CTIX announced a $30 million stock purchase agreement with Aspire Capital Fund, LLC. Pursuant to the Agreement, Aspire has committed to purchase over the next 3 years up to $30 million of Cellceutix’s common stock based on the prevailing market prices at the time of each sale. The timing of the purchases will be at the sole discretion of Cellceutix. Aspire Capital has previously provided the Company with $30 million in equity capital in two similar transactions.
Steven G. Martin of Aspire Capital Fund, LLC said “We are pleased to continue our successful, long-term relationship with Cellceutix by entering into a new $30 million transaction. Over the last several years, Aspire Capital has completed two similar transactions with the Company totaling $30 million. During that time, Cellceutix has made tremendous progress in advancing the development of its key assets including Brilacidin, Kevetrin, and Prurisol. We were pleased with the results from the phase 2B trial of Brilacidin for ABSSSI. We are also pleased to see Kevetrin showing promising signs of activity and tolerability. We continue to believe in the Company’s potential and are excited about the upcoming milestones in 2015.”
Currently trading at a $325 million market valuation CTIX has been the darling of the bb’s in recent years running from pennies to $4.93 a share. The Company is currently fully funded with over $7 million in the treasury. The stock is just now coming into the price range where they will be noticed by the primary players of biotechnology who could be all over this one. We will be updating on CTIX when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CTIX.
ARMOR study reports changes in antibiotic resistance levels
http://www.healio.com/ophthalmology/retina-vitreous/news/online/%7Bf50a5b29-14a1-4217-9722-87213811a2ae%7D/armor-study-reports-changes-in-antibiotic-resistance-levels
Hey Buddy,
Your too funny....... broke but have 3 unfilled orders sitting LOL!......
I'm overloaded myself and have been selling other plays to add. This adding more CTIX is against my trading rules as I usually don't add to those going down and have up to near 8% of total value in it.
I really feel bad for those that were drove to sell this dump.
May CTIX fly high soon,
Fletch
Edit : And may our recent sellers get back in and ride up too!
A reminder of views from Cellceutix,
Fletch
http://cellceutix.com/cellceutix-provides-corporate-update/#sthash.rN2Jx7uP.dpbs
NASDAQ Uplisting
Our NASDAQ application is in process. We made our selections and now received confirmation of acceptance of positions for new members to the Company’s Board of Directors and committees required to move to the NASDAQ exchange. This information has been prepared in the form of an 8-K filing for submission to the Securities and Exchange Commission (SEC) and is currently being reviewed by our SEC counsel. Under guidance of our legal counsel, we will be publicly releasing this information simultaneously with the 8-K submission.
“There are many exciting developments ongoing at Cellceutix, both at the corporate level and from a drug development perspective,” commented Leo Ehrlich, Chief Executive Officer at Cellceutix. ”We have always held that the best approach to build shareholder value is to conduct multiple projects concurrently. We are executing efficiently at this business model, targeting large markets with novel drugs, while running a lean operation. In a relatively short period of time, we have grown exponentially and will soon have several Phase 2 trials and a Phase 3 study happening as we stand in the best financial position in the Company’s history.”
Sign-up for Cellceutix email alerts is available at
- See more at: http://cellceutix.com/cellceutix-provides-corporate-update/#sthash.rN2Jx7uP.dpuf
Hey Buddy,
Yes, CTIX should go up and I think some that are waiting on the sidelines are making a big mistake. By waiting until the Nasdaq news is out, they'll miss out on a lot of a run up. Too bad we had some calling for a rally by certain dates and the news that came out turned into sell that news. IMO, it was done to help, just the way it turned out.
Glad your back with us,
Fletch
Uplisting good or what,
Fletch
http://www.kcsa.com/blog/?p=539
Uplisting to a Higher Exchange: Is it the Right Thing for your Company?
Posted by Phil Carlson on July 16, 2012
In the world of investor relations, most independent agencies, like KCSA, tend to work with several small companies whose stock trades at a relatively low price and market capitalization. These stocks are typically known as microcap or penny stocks (By definition, microcap stocks have a market capitalization between $50 million and $300 million). Many of these companies trade over-the-counter (OTC) and are quoted on OTC systems such as the OTC Bulletin Board (OTCBB), OTCQB, OTCQX and OTC Pink, formerly known as the “Pink Sheets.”
To many, companies that trade on such exchanges are typically categorized as “riskier” investments. This is due to the lack of public information on these companies as well as the fact that there are no minimum quantitative listing standards for these exchanges. Many institutional investors have by-laws that prevent them from investing in companies that trade on OTC exchanges and retail investors are usually asked to sign a waiver from their broker/dealer stating they understand the risks associated with OTC exchange traded stocks. Even online brokerages have restrictions when it comes to OTC stocks. This is a big disadvantage for a small company seeking liquidity.
So how does a company go about increasing its visibility with institutional investors as well as drive liquidity? My advice: “UPLIST TO A MAJOR EXCHANGE!” Over the past few months at KCSA, we have helped our clients Neonode and Attunity uplist to major exchanges – Neonode, has already seen an increase in volume and stock price.
According to a recent NASDAQ study, [CM1] OTC companies upgrading to NASDAQ had an average 3 month average daily volume (ADV) of 59,509 shares prior to uplisting compared to 137,905 shares after uplisting. That’s a decent upswing in terms of volume.
In addition to increased liquidity, uplisting to a major exchange provides your company with regulatory oversight in terms of monitoring against potential trading violations and listing qualifications. Companies get the opportunity to be included in indexes such as the NASDAQ and S&P as well as the Russell 2000 & 3000. Companies also have a greater chance to receive analyst coverage if uplisting to a major exchange. When engaged in merger or acquisition talks, a company’s stock is viewed as a more attractive bargaining chip if it’s listed on a national or global exchange. Do you see where I’m going here?
As a CEO you may wonder, “What do I need to do to uplist to a major exchange?” The chart below outlines the quantitative requirements to uplist to the NASDAQ Capital Market and NYSE MKT (formerly known as the AMEX). These two exchanges are typically the next step for a company uplisting from one of the OTC exchanges.
Companies must adhere to additional requirements, such as corporate governance and exchange listing fees, in order to uplist to a higher exchange. However, in my opinion, if a company has the opportunity to uplist to a major exchange, it should make the move. As along as the management team is successfully executing on its growth strategy and producing a constant flow of news, an uplisting not only benefits the company but also benefits the shareholder.
At least they have heard of us,
Fletch
http://www.nasdaq.com/symbol/ctix
Not sure we are doing anything to SP but this is my first OTC low vol. play..........so ??,
Fletch
I did not know they had so many in pipeline. For most....old stuff.
From Bloomberg:
http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=CTIX
Cellceutix Corp (CTIX) Details
Cellceutix Corporation, a clinical stage biopharmaceutical company, focuses on discovering and developing small molecule drugs to treat drug-resistant cancers, psoriasis, autism, and inflammatory diseases. Its flagship compounds include Kevetrin, an anti-cancer compound that is in Phase I clinical trial for the treatment of cancer; Prurisol, an anti-psoriasis drug candidate that has completed Phase I clinical trial; and Brilacidin, an antibiotic candidate for the treatment of diabetic foot ulcer infections, and other indications, such as ophthalmic and otitic infections, as well as for other skin infections and oral mucositis. The company’s preclinical stage compounds comprise KM 391 for the treatment of autism; KM 277 for the treatment of rheumatoid arthritis; KM 278 for the treatment of arthritis/asthma; KM 362 for the treatment of MS/ALS/Parkinson’s disease; KM-3174 for the treatment of cancer; and KM-732 for hypertensive emergency, as well as Delparantag, a synthetic small-molecule for the treatment of other diseases, including chronic obstructive pulmonary disease. In addition, its other product candidates include compounds active against other gram-negative bacterias, malaria, tuberculosis, biowarfare pathogens, and PolyCide antimicrobial biomaterials. The company was founded in 2007 and is headquartered in Beverly, Massachusetts.
Detailed CTIX:US Company Description...
Sure......just as I hit submit post.......we crash like .10. That was a big order that was filled.
Go CTIX,
Fletch
Very good presentation.......He is easy to understand and speaks well.
Thanks,
Fletch
Yes, surprised the share price ended as low as it did. Also glad I sold some of a play that wasn't doing that well, to buy more under 3. IMO there isn't a huge seller out there. Several different times my orders will fill with several small buys which means to me that there isn't a big seller. Why did we sell off? I think it's still the same small group holding or trading CTIX. I try to never predict but think the Nasdaq listing brings us a lot more fresh $,
Fletch